Sirnaomics Partners with Chinese Pharma on Wound-Healing Drug
December 02, 2010
Sirnaomics Partners with Chinese Pharma on Wound-Healing Drug
The drug, STP705, uses a polymeric nanoparticle to enhance topical delivery of siRNAs targeting the TGF-beta 1 and Cox-2 genes to open wounds, Sirnaomics said.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Sirnaomics Inks Ocular Disease Drug Deal with Chinese Drugmaker
June 30, 2011 / Gene Silencing News - Sirnaomics Aims to Move Wound-Healing Drug into Phase I Next Year
June 24, 2010 / Gene Silencing News - Sirnaomics Nears Phase I Study of Wound-Healing Drug as It Eyes the microRNA Field
June 28, 2012 / Gene Silencing News - NIH Awards $1.3M in siRNA Delivery-Related Grants Last Month
April 12, 2012 / Gene Silencing News - Undisclosed Pharma to Evaluate Silence siRNA-Delivery Technology
September 29, 2011 / Gene Silencing News